focus -WSS

focus

author：explore 2025-10-01 02:14:13 - browse：11337

ASH19 CAR-T — Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

That sounds staggering to many patients — but it’s far less than analysts expected.

The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Australia’s approach to dialysis celebrates life

hotspot

entertainment

WSS

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Winners, losers from Medicare’s list of drugs subject to price talks

AstraZeneca bets AAV gene therapy will still deliver the goods

Why depression after traumatic brain injury is distinct

Psilocybin's anti

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

explore

focus

entertainment

How to save PrEP access — and even expand it

AstraZeneca challenges Medicare drug negotiation program

Hollywood unions extend contract negotiations for actors

Radiation, mainstay of cancer treatment, begins a fade

Cancer drug shortages should be causing more outrage

Winners, losers from Medicare’s list of drugs subject to price talks

Novavax promises a turnaround & Lilly roils the obesity market

Appeals court upholds limits to abortion pill

Medical leaders decry Supreme Court decision on affirmative action

Complete sequence of Y chromosome published for first time

hotspot

FDA advisers back CAR

Diversity in medical illustrations gets boost from Chidiebere Ibe

Amid AI frenzy, a top HHS official's quest to create safeguards

Pushing for an NIH office for post

Boston's new lab space is opening empty

John Green on his newest strategy for fighting tuberculosis

hotspot

hotspot

entertainment

focus